Turning discoveries into therapies
Here’s what’s in our Pipeline:
*40+ programs in the combined therapeutic areas. As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets.
Our current clinical programs
CD200R1
This 23andMe-owned immuno-oncology program is currently in Phase 1 in patients with advanced solid tumors (NCT05199272).
CD96
This immuno-oncology program with GSK is currently in Phase 1 in patients with advanced solid tumors (NCT04446351).